Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $109
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Axsome Therapeutics (AXSM) and raises the price target from $108 to $109.
March 28, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh reaffirms a Buy rating on Axsome Therapeutics and increases the price target to $109.
The increase in price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100